Submissions for Postapproval Modifications to a Combination Product Approved Under a BLA, NDA, or PMA: Draft Guidance for Industry and FDA Staff
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
January 18, 2013
May 13, 2021
e6c53755-5cb5-49ce-9d67-07a008f66761
Related Documents
Cross-Center Master Files: Where to Submit: Draft Guidance for Industry
Guidance DocumentNovember 25, 2025Office of the Commissioner
Essential Drug Delivery Outputs for Devices Intended to Deliver Drugs and Biological Products: Draft Guidance for Industry
Guidance DocumentJune 28, 2024Office of the Commissioner
Unique Device Identifier Requirements for Combination Products: Draft Guidance for Industry
Guidance DocumentJune 25, 2025Office of the Commissioner
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox